Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Health Impact of Juvenile Idiopathic Arthritis
JIA is the most common rheumatic disease of childhood. Prevalence of the disease is estimated to be between 7 to 400 per 100,000 children.
As a chronic, disabling disease, JIA interferes with growth and development and causes psychological stress. Left unchecked, the course of disease results in irreversible joint damage and life-long disability. There is no cure for JIA.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic
- Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58(1):15-25. PMID: 18163481.
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066 -I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
- Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29(7):1520-30. PMID: 12136914.
Your slide tray is being processed.